Jane Street’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-98,308
| Closed | -$397K | – | 9746 |
|
|
2025
Q1 | $397K | Buy |
+98,308
| New | +$328K | ﹤0.01% | 7284 |
|
|
2024
Q1 | – | Sell |
-40,541
| Closed | -$92.8K | – | 9262 |
|
|
2023
Q4 | $92.8K | Buy |
+40,541
| New | +$88.3K | ﹤0.01% | 8610 |
|
|
2023
Q1 | – | Sell |
-10,042
| Closed | -$51.3K | – | 9116 |
|
|
2022
Q4 | $51.3K | Buy |
10,042
+3,880
| +63% | +$28K | ﹤0.01% | 8358 |
|
|
2022
Q3 | $64K | Buy |
6,162
+3,052
| +98% | +$36.4K | ﹤0.01% | 8831 |
|
|
2022
Q2 | $32K | Buy |
+3,110
| New | +$40.7K | ﹤0.01% | 9037 |
|
|
2021
Q4 | – | Sell |
-1,219
| Closed | -$40K | – | 10126 |
|
|
2021
Q3 | $40K | Sell |
1,219
-1,452
| -54% | -$42.9K | ﹤0.01% | 9615 |
|
|
2021
Q2 | $79K | Buy |
+2,671
| New | +$74K | ﹤0.01% | 9358 |
|
|
2021
Q1 | – | Sell |
-1,378
| Closed | -$37K | – | 9124 |
|
|
2020
Q4 | $37K | Buy |
+1,378
| New | +$34.9K | ﹤0.01% | 7344 |
|
|
2019
Q3 | – | Sell |
-3,152
| Closed | -$95K | – | 5131 |
|
|
2019
Q2 | $95K | Buy |
+3,152
| New | +$124K | ﹤0.01% | 4864 |
|
Jane Street's CKPT Position: Q2 2025 in Review
Jane Street sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 98,308 shares — an estimated $397K sold.
Jane Street first reported a position in CKPT in Q2 2019 and held it in 9 quarters. The position peaked at $397K in Q1 2025. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- Jane Street reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- Jane Street sold 98,308 Checkpoint Therapeutics shares in Q2 2025, an estimated $397K.
- Jane Street first reported a position in Checkpoint Therapeutics in Q2 2019 and held it in 9 quarters.
- Jane Street's Checkpoint Therapeutics position peaked at $397K in Q1 2025.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on Jane Street's 13F filing for Q2 2025, filed 14 Aug 2025.